Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 22, 2024

Preclinical development of a dual targeting bicistronic gene therapy approach for the treatment of wet age-related macular degeneration

View Full Paper
Ask AI
Bookmark
Share

Authors

LTLawrence C. S. TamJJJosephine JoelDSDimitris Stampoulis

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Tam et al. (2024) studied this question.

synapsesocial.com/papers/68e5f853b6db64358758ca48https://doi.org/10.21203/rs.3.rs-4636180/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Optimisation of the foot-and-mouth disease virus 2A co-expression system for biomedical applications2013 · 67 citations
  2. 2Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells2015 · 209 citations
  3. 32A and 2A-like Sequences: Distribution in Different Virus Species and Applications in Biotechnology2021 · 33 citations
  4. 4Suppression of Choroidal Neovascularization by AAV-Based Dual-Acting Antiangiogenic Gene Therapy2019 · 65 citations
  5. 5Longer-Term Anti-VEGF Therapy Outcomes in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Vein Occlusion-Related Macular Edema2022 · 56 citations